 PARIS CAMBRIDGE, Mass.--BUSINESS WIRE-- cancer--Regulatory News: NANOBIOTIX Euronext : NANO NASDAQ: NBTX the Company, a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced its revenues for the fourth quarter and full year ended December 31, 2020. Full Year 2020 Revenue Twelve Months Ended December 31st K 2020 2019 Revenues 50 68 Of which licenses - - Of which services 50 